Absolutely they could, but with the patent protections for OA/BMEL using PPS - they've got to infringe on PAR in order to do so for a long while yet.
http://www.paradigmbiopharma.com/investors/ip-patents-trademarks
Added to this is the time it takes to develop and then come in as a new entrant where PAR will have potentially scooped up a market leading position. I think it a reasonable argument that it would just be easier for a large pharma to just skip the cue and just lob a takeover bid - which is what I'm basing my investment on. i.e. positive Ph2b results -> risk-off investment and large jump in share price -> number of suitors to lob bids for licensing arrangement (inc in share price again) -> get fed up and just lob a bid for takeover (at reasonable premium). My thoughts anyway.
Absolutely they could, but with the patent protections for...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.055(20.4%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 33.5¢ | 27.5¢ | $1.328M | 4.323M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 152597 | 4 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
